Akebia Therapeutics Stock Price and Value Analysis

Should you buy Akebia Therapeutics stock? (NasdaqGM:AKBA). Let's see how it does in our automated value investing analysis system.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Akebia Therapeutics to reach your target.

Target type
AdvantagesDisadvantagesNeutral
  • This company has stable growth.
  • This company is not making money.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the AKBA Numbers

AKBA Price
(Akebia Therapeutics stock price per share)
$1.30
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 24%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 19,177,371 shares shorted. With 262,013,191 shares available for purchase and an average trading volume over the past 10 trading days of 3,356,440, it would take at least 5.714 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Is Akebia Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Akebia Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Advertisement supports free stock analysis content.

Should You Buy AKBA Stock?

Does Akebia Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

We don't yet have enough financial history for Akebia Therapeutics to produce a full worked example. Check back as more data becomes available, or see the current price and research links below.